Full steam ahead on EU medtech regulatory reforms
This article was originally published in SRA
EU medtech industry association Eucomed is putting a positive spin on yesterday’s vote on the revision of the Medical Devices Directive at the European Parliament, saying it paves the way to achieve balanced rules on medical devices1. The scene is now set for a new Medical Device Regulation and a new In Vitro Diagnostics Regulation to be on the statute books by the end of the current Parliamentary term – ie April 20142,3.
You may also be interested in...
Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with seven new products including Roche's Polivy for treating diffuse large B-cell lymphoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).